Memorial Sloan Kettering Cancer Center;Eureka Therapeutics, Inc.
发明人:
Katharine HSU,Nai-Kong V. Cheung,Su YAN,Yiyang XU,Jingyi XIANG,Cheng LIU
申请号：
US16484451
公开号：
US20200031927A1
申请日:
2018.02.26
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The disclosure provides antibody agents that bind to inhibitory human killer immunoglobulin-like receptors (KIRs). Particular antibody agents of the disclosure include antibody agents that bind to KIR3DL1 (also known as CD158e). Also provided are related nucleic acids, vectors, compositions and methods of using KIR-binding antibody agents of the present technology.
